Standard Biotools Stock Performance
| LAB Stock | USD 1.40 0.07 4.76% |
On a scale of 0 to 100, Standard Biotools holds a performance score of 6. The entity has a beta of 2.86, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Standard Biotools will likely underperform. Please check Standard Biotools' jensen alpha, maximum drawdown, and the relationship between the coefficient of variation and sortino ratio , to make a quick decision on whether Standard Biotools' existing price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Standard Biotools are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Standard Biotools sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Standard BioTools Q1 2025 Earnings Preview | 05/05/2025 |
2 | Disposition of 6364 shares by Hanjoon Kim of Standard Biotools at 1.05 subject to Rule 16b-3 | 05/20/2025 |
3 | Disposition of 1407 shares by Hanjoon Kim of Standard Biotools at 1.03 subject to Rule 16b-3 | 05/21/2025 |
4 | Disposition of 12536 shares by Sean Mackay of Standard Biotools at 1.002 subject to Rule 16b-3 | 05/22/2025 |
5 | Disposition of 5473 shares by Michael Egholm of Standard Biotools at 0.941 subject to Rule 16b-3 | 05/23/2025 |
6 | Standard BioTools Inc. SVP Sean Mackay Sells 13,217 Shares | 05/29/2025 |
7 | With 48 percent stake, Standard BioTools Inc. seems to have captured institutional investors interest | 06/18/2025 |
8 | Acquisition by Witney Frank of 125660 shares of Standard Biotools at 1.05 subject to Rule 16b-3 | 06/20/2025 |
9 | Standard BioTools Soars on SomaLogic Sale to Illumina for 425M | 06/23/2025 |
10 | ENCLAVE RACE LAB DRIVING SIMULATOR LOUNGE OPENS AT THE MOTOR ENCLAVE | 06/24/2025 |
11 | Standard BioTools Inc. dropped from Russell 3000E Growth Index - MarketScreener | 06/30/2025 |
12 | DESIGNABLE FASHION LAUNCHES NEW DIGITAL LAB TO EMPOWER FASHION ENTREPRENEURS | 07/16/2025 |
13 | What drives Standard BioTools Inc. stock price - Triple returns potential - Autocar Professional | 07/22/2025 |
14 | What drives Standard BioTools Inc. stock price - Exceptional portfolio growth - Autocar Professional | 07/25/2025 |
| Begin Period Cash Flow | 52.5 M | |
| Total Cashflows From Investing Activities | 363.2 M |
Standard Biotools Relative Risk vs. Return Landscape
If you would invest 118.00 in Standard Biotools on April 28, 2025 and sell it today you would earn a total of 22.00 from holding Standard Biotools or generate 18.64% return on investment over 90 days. Standard Biotools is generating 0.4011% of daily returns assuming volatility of 5.1897% on return distribution over 90 days investment horizon. In other words, 46% of stocks are less volatile than Standard, and above 92% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Standard Biotools Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Standard Biotools' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Standard Biotools, and traders can use it to determine the average amount a Standard Biotools' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0773
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LAB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.19 actual daily | 46 54% of assets are more volatile |
Expected Return
| 0.4 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Standard Biotools is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Standard Biotools by adding it to a well-diversified portfolio.
Standard Biotools Fundamentals Growth
Standard Stock prices reflect investors' perceptions of the future prospects and financial health of Standard Biotools, and Standard Biotools fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Standard Stock performance.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.78) % | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 279.21 M | ||||
| Shares Outstanding | 361.24 M | ||||
| Price To Earning | (2.52) X | ||||
| Price To Book | 1.11 X | ||||
| Price To Sales | 2.98 X | ||||
| Revenue | 174.43 M | ||||
| Gross Profit | 79.81 M | ||||
| EBITDA | (118.14 M) | ||||
| Net Income | (138.88 M) | ||||
| Cash And Equivalents | 81.31 M | ||||
| Cash Per Share | 2.68 X | ||||
| Total Debt | 33 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 5.87 X | ||||
| Book Value Per Share | 1.23 X | ||||
| Cash Flow From Operations | (143.45 M) | ||||
| Earnings Per Share | (0.32) X | ||||
| Market Capitalization | 505.74 M | ||||
| Total Asset | 612.34 M | ||||
| Retained Earnings | (1.19 B) | ||||
| Working Capital | 309.99 M | ||||
About Standard Biotools Performance
By analyzing Standard Biotools' fundamental ratios, stakeholders can gain valuable insights into Standard Biotools' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Standard Biotools has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Standard Biotools has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 164.90 | 196.27 | |
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.29) | (0.31) |
Things to note about Standard Biotools performance evaluation
Checking the ongoing alerts about Standard Biotools for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Standard Biotools help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Standard Biotools had very high historical volatility over the last 90 days | |
| Standard Biotools may become a speculative penny stock | |
| The company reported the last year's revenue of 174.43 M. Reported Net Loss for the year was (138.88 M) with profit before taxes, overhead, and interest of 79.81 M. | |
| Standard Biotools has about 81.31 M in cash with (143.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Standard Biotools has a poor financial position based on the latest SEC disclosures | |
| Roughly 73.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: What drives Standard BioTools Inc. stock price - Exceptional portfolio growth - Autocar Professional |
- Analyzing Standard Biotools' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Standard Biotools' stock is overvalued or undervalued compared to its peers.
- Examining Standard Biotools' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Standard Biotools' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Standard Biotools' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Standard Biotools' stock. These opinions can provide insight into Standard Biotools' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Standard Stock analysis
When running Standard Biotools' price analysis, check to measure Standard Biotools' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Standard Biotools is operating at the current time. Most of Standard Biotools' value examination focuses on studying past and present price action to predict the probability of Standard Biotools' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Standard Biotools' price. Additionally, you may evaluate how the addition of Standard Biotools to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |